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Neurofibromatosis type 1 is a common autosomal
dominant disorder (incidence 1:3500) characterized by
lesions that include neural crest derivatives such as
Schwann cells and melanocytes. A critical event in
the pathogenesis of neurofibromatosis type 1 is the
heterozygous germ-line loss of the tumor suppressor
gene NF1. Additional genetic and/or epigenetic events
have been posited, including various alterations in
growth factor expression. By in situ hybridization
and immunohistochemistry, we demonstrate aberrant
expression of the angiogenic and tumorigenic growth
factor midkine in the skin of patients with neuro-
fibromatosis type 1, but not normal individuals. We
Neurofibromatosis type 1 (NF1) is a commonautosomal dominant disorder (incidence 1:3500)characterized by abnormalities of neural crest deriv-atives such as Schwann cells and melanocytes(Gutmann and Collins, 1995). These abnormalities
are often cutaneous in nature, and are manifested as multiple dermal
neurofibromas, cafe´-au-lait maculas, abnormal freckling, Lisch nod-
ules, and hyperpigmentation (Gutmann and Collins, 1995). The
heterozygous germ-line loss of NF1 is thought to be the critical
event in the pathogenesis of NF1. Additional secondary genetic
and epigenetic events such as loss of heterozygosity (Sawada et al,
1996) and growth factor dysregulation may be involved (De Clue
et al, 1991; Gutmann et al, 1991; Bernards, 1995). We have
previously reported that loss of both alleles of NF1 in murine
Schwann cells results in the upregulation of the growth factor
midkine (MK). MK is a secreted 13 kDa heparin-binding polypep-
tide that is highly expressed during mouse embryogenesis in the
neuroectoderm and regions of secondary epithelial–mesenchymal
induction (Muramatsu et al, 1993; Mitsiadis et al, 1995). In the
adult, residual MK expression is detected in kidney, intestine,
and cerebellum (Kadomatsu et al, 1990; Nakamoto et al, 1992;
Muramatsu et al, 1993; Matsumoto et al, 1994). Overexpression of
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demonstrate that midkine expression is independent
of the presence of neurofibromas, and thus appears
to be associated with mutations in the NF1 gene.
Furthermore, midkine-containing culture media is
shown to stimulate the growth of human endothelial
and neurofibroma-derived cells. In conclusion, we
introduce the skin as a source of dysregulated growth
factors in neurofibromatosis type 1, and suggest the
further study of the angiogenic factor midkine in
neurofibromatosis type 1 pathogenesis. Key words:
neurofibromin/growth factor/skin/keratinocytes. J Invest
Dermatol 113:398–402, 1999
MK in the adult has been found to be associated with a variety of
tumors (Garver et al, 1994; Nakagawara et al, 1995; O’Brien et al,
1996), and is thought to promote angiogenesis and tumorigenesis
(Choudhuri et al, 1997; Kadomatsu et al, 1997). In this study, we
investigated the expression of MK in the skin of NF1 patients and
found overexpression that was independent of the presence of
a tumor.
MATERIALS AND METHODS
Tissues and cell lines Neurofibroma and normal skin samples were
obtained from the Lombardi Cancer Center tissue facility. The cell line
Hs422T of fibroblast morphology is derived from the neurofibroma of an
NF1 patient and was obtained from American Tissue Type Culture
Collection (ATCC, Rockville, MD). Human umbilical vein endothelial
cells (HUVEC) were obtained from the Lombardi Cancer Center cell
culture core. SW-13, SW-13 transfected with an empty pRC/CMV
(Invitrogen, San Diego, CA) control vector, and SW-13 transfected with
a pRC/CMV-human MK expression construct which contains full length
cDNA under control of a cytomegalovirus (CMV) promoter, were gener-
ated essentially as described for the MK-homolog pleiotrophin (Fang et al,
1992; Buchert-Sale, unpublished). G418 resistant cell clones transfected
with the pRC/CMV-human MK expression construct were screened for
high expression of MK by immunoblotting and clone MK6 with highest
expression levels was used for further studies.
Northern analysis RNA was isolated from human skin samples obtained
from blepharoplasty. For the northern blots, 20 µg of total RNA from
each tissue sample was separated in an agarose gel and transferred on to
nitrocellulose. Blots were hybridized with a [32P]-labeled full length human
cDNA probe for MK. A [32P]-labeled 0.5 kb cDNA fragment of the
glucose-6-phosphate dehydrogenase housekeeping gene was used for con-
trol hybridizations (not shown). Hybridization was carried out in buffer
containing 50% formamide at 42°C. Blots were subsequently washed in
0.1 3 sodium citrate/chloride buffer, 0.1% sodium dodecyl sulfate at 65°C
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prior to exposure to autoradiographic film at –70°C using intensifying
screens for 24 h.
In situ hybridization (ISH) Sense and anti-sense digoxigenin-labeled
(Boehringer Mannheim, Indianapolis, IN) riboprobes for human MK and
fibroblast growth factor type 2 (FGF-2) were transcribed in vitro for 2 h at
42°C in the presence of 0.25 µM digoxigenin conjugated dUTP from
1 mg of linearized plasmid containing full-length sense and anti-sense
cDNA. Transcripts were treated with RNase-free DNase I, ethanol-
precipitated, and resuspended in 100 ml diethylpyrocarbonate-treated water.
Paraffin-embedded tissue sections for dermal neurofibromas, and normal
skin were obtained from the Lombardi Cancer Center Tumor Bank. ISH
was essentially performed as described before (Panoskaltsis-Mortari and
Bucy, 1995). Briefly, 10 µm thick tissue sections on silanized slides were
washed, acetylated, and treated overnight at 55°C with hybridization buffer
containing heat-denatured sense or anti-sense riboprobes. Sections were
washed after hybridization at high stringency, immersed in blocking buffer,
and immunohistochemistry was performed using an alkaline phosphatase-
conjugated sheep-anti-digoxigenin antibody (1:500), following the manu-
facturer’s instructions (Boehringer Mannheim). Chromogen substrate for
alkaline phosphatase (nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-
phosphate) was added and the reaction was allowed to proceed overnight
at 4°C. Color development was stopped with 10 mM Tris–HCl, pH 8.0,
1 mM ethylenediamine tetraacetic acid and tissue was mounted in an
aqueous mounting medium.
Immunohistochemistry Paraffin-embedded neurofibroma and normal
skin tissue sections were incubated overnight at 55°C, microwaved at high
power for 10 min (to remove remaining paraffin and to unmask antigen;
Cattoretti et al, 1993), cooled for 5 min at room temperature and treated
with xylene for 10 min. After two washes in 100% ethanol for 5 min each,
the slides were rehydrated and washed in H2O and phosphate-buffered
saline (PBS) for 1 min each. Slides were then treated in PBS/1% (vol/vol)
acetic acid at 80°C for 10 min. The slides were then cooled to room
temperature and washed twice in PBS. The tissue was then blocked with
5% goat normal serum in PBS/2% bovine serum albumin for 30 min. For
immunohistochemistry, a polyclonal rabbit anti-MK (1:1000) antibody was
used (anti-MK antibody was a generous gift from Dr. A. Seddon; Mahoney
et al, 1996). Antibody was applied overnight at 4°C, and slides were
washed three times in PBS/Tween. A biotinylated goat anti-rabbit second-
ary antibody (1:500) (Vector, Burlingame, CA) was then applied for 30 min
at room temperature, followed by three washes in PBS/Tween. For
detection and visualization, the ABC system (Vector) was used according
to the manufacturer’s protocol with 0.1 mg per ml diaminobenzidine as
substrate. Slides were counterstained with hematoxylin for 1 min. Dehyd-
rated in ethanol and xylene, and coverslipped using a nonaqueous mount-
ing medium.
Partial purification of MK One hundred milliliters of media condi-
tioned for 24 h by SW-13 cells (wild-type or transfected MK6 cells) were
loaded on to 1 ml heparin-Sepharose columns (Pharmacia Biotech Inc.,
Piscataway, NJ), washed and the bound proteins were eluted with a step
gradient of 3 ml each of 0.4 M, 0.9 M, and 2.0 M NaCl in 10 mM Tris
buffer (pH 7.5) as described for the purification of pleiotrophin (Fang et al,
1992). For quantitation of the purified MK, rabbit anti-MK antibody
(Mahoney et al, 1996) was used at a titer of 1:2000. This antibody detects
one single band of about 17 kDa in western blots as expected for MK and
does not recognize any protein in SW-13 cells that do not express MK.
Heparin-affinity chromatography fractions were quantitated for MK by
slot-blot analysis (Fang et al, 1992). Human recombinant MK produced in
Escherichia coli (R&D Systems, Minneapolis, MN) was used as a standard.
Recombinant MK protein was only found in the 0.9 M NaCl fraction
from conditioned medium of MK6 cells. Purified MK was used at a
maximal concentration of µ8 ng per ml for proliferation assays.
Proliferation assays Cell lines used to collect conditioned media were
SW13 (adrenal carcinoma), SW-13 cells transfected with the pRC/CMV
control vector, and an SW13 cell line overexpressing human recombinant
MK from an MK-pRC/CMV expression construct (MK6). Cells were
cultured to confluence in a T75 flask, washed several times in PBS, and
5 ml serum-free media (Iscove’s modified essential medium) was added
and collected 24 h later. Media were used directly after centrifugation and
filtration to remove cellular elements.
Partially purified MK (0.9 M NaCl heparin fractions from MK 6 cells)
was also used for HUVEC assays. MK concentration in the 0.9 M NaCl
heparin fractions was estimated at 8 ng per 50 µl by immunoblotting. As
a control, 0.9 M NaCl heparin fractions from conditioned medium of
SW13 cells transfected with an empty vector were used.
HUVEC and Hs422T neurofibroma derived cells, respectively, were
plated at 1000 cells per well in a fibronectin-coated 96 well plate in
IMEM/10% fetal bovine serum. After 16 h, 100 µl of serum-free media,
SW13, or MK6 conditioned media were added in triplicate. For dose–
response analysis, heparin-affinity purified MK was used and HUVEC cells
were plated in fibronectin coated 12-well plates at 5000 cells per well.
After 16 h, 1 ml of serum-free medium supplemented with 50, 25, 10,
and 0 µl of the 0.9 M NaCl heparin fraction from MK6 cells and 50 µl
0.9 M NaCl fraction from control SW13 cells was added. At day 4 after
stimulation, the media were replaced with 100 µl IMEM/10% fetal bovine
serum 1 10 µl WST-1 colorimetric reagent (Boehringer Mannheim) or
1 ml IMEM/10% fetal bovine serum 1 100 µl WST-1, respectively. At
30 min after addition of reagent, plates were analyzed at a reference λ of
600 nm and test λ of 450 nm.
RESULTS
Midkine is differentially expressed in the skin of NF1
patients Neurofibromin is expressed in Schwann cells (Nakamura
et al, 1994), and its loss in NF1–/– Schwann cells results in the
upregulation of MK.1 Because neurofibromin is also expressed
in keratinocytes and melanocytes (Malhotra and Ratner, 1994;
Hermonen et al, 1995), and because the symptoms of NF1
are predominantly cutaneous, we investigated whether MK was
abnormally upregulated in the skin of NF1 patients.
ISH revealed dramatic expression of MK transcript in the
keratinocytes of NF1 patients. MK mRNA was detected in the
skin of NF1 patients in all epidermal layers in regions overlying
neurofibromas (n 5 4) (Fig 1a), and was also found in some
subepidermal cells of unclear origin (Fig 1a). These subepidermal
MK positive cells might be dermal fibroblast or tumor-derived
fibroblasts. Importantly, skin over a solitary neurofibroma from a
non-NF1 subject demonstrated little to no MK mRNA expression
(n 5 1) (Fig 1b), suggesting that expression is particular to
NF1 patients.
Skin without phenotypic abnormality from an NF1 patient was
also found to express MK mRNA in the epidermal, but not in the
dermal layers (n 5 1) (Fig 1c), indicating that subepidermal, MK
positive cells seen in Fig 1(a) are due to underlying neurofibromas
which are positive for MK (not shown). In contrast, normal skin
from healthy subjects was negative for MK mRNA expression by
ISH (n 5 4) (Fig 1d) and northern analysis (n 5 6) (not shown).
No signal was detected using a MK sense riboprobe (not shown).
These data strongly suggest that the induction of MK expression
in neurofibromin-deficient keratinocytes is linked to the NF1
mutation itself, and not simply to the presence of an underlying
neurofibroma.
We found that MK mRNA expression in the keratinocytes of
NF1 patients is paralleled by an identical pattern of MK protein
expression, as shown by immunohistochemistry (n 5 3 for NF1
skin over a neurofibroma, n 5 3 for NF1 skin without phenotypic
abnormality) (Fig 1e). Although MK mRNA was not detected in
the dermis of NF1 skin without phenotypic abnormality, MK
protein did appear to be present probably diffusing from the MK
expressing epidermal layer. MK is a secreted protein, and has
previously been detected in areas where transcript is not expressed
(Muramatsu et al, 1993). In contrast, the epidermal and dermal
layers of normal human skin are MK negative by immunohisto-
chemistry (n 5 3) (Fig 1f), as was previously demonstrated (Inazumi
et al, 1997). No MK protein was detected in skin overlaying non-
NF1 neurofibromas (n 5 2) (not shown). These results are
summarized in Table I. Staining of the stratum corneum is
attributable to nonspecific antibody binding, as this was found in
1Mashour G, Ratner N, Martuza RL, Wellstein A, Kurtz A: Midkine
is differentially expressed in neurofibromin-deficient Schwann cells and
human neurofibromas. Society for Neuroscience 27th Annual Meeting
23(1):43.19, 1997 (Abstr.)
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Figure 1. MK is expressed in NF1 but not normal skin. White
asterisks: MK-positive epidermal layer of the skin (a, c, e). Black asterisks:
MK-negative epidermal layer of the skin (b, d, f) and basic FGF negative
epidermal layer of the skin (g, h). (a) ISH of MK anti-sense digoxigenin-
labeled riboprobe to skin with a dermal neurofibroma from an NF1 patient
(n 5 4). Subepidermal MK-positive cells are of unclear histotype and
might present dermal fibroblast or neurofibroma derived fibroblasts. Arrows,
melanocytes in the basal layer. (b) ISH of MK anti-sense to skin with a
sporadic dermal neurofibroma from a non-NF1 patient (n 5 1). Note the
much weaker subepidermal tumor cell labeling. (c) ISH of MK anti-sense
to skin without phenotypic abnormality from an NF1 patient (n 5 1). (d)
ISH of MK anti-sense to skin without phenotypic abnormality from a
healthy subject (n 5 4). (e) MK immunohistochemistry of skin without
phenotypic abnormality from an NF1 patient (n 5 3). (f) MK
immunohistochemistry of skin without phenotypic abnormality from a
healthy subject (n 5 3). (g) ISH of FGF-2 anti-sense digoxigenin-labeled
riboprobe to a dermal neurofibroma from an NF1 patient (n 5 3). Arrow,
blood vessel. (h) ISH of FGF-2 anti-sense to normal skin from a healthy
subject (n 5 3). Scale bars: 200 µm.
Table I. MK expression in NF1 and non-NF1 skina
Sample In situ hybridization Northern analysis Immunolocalization
NF1 skin over neurofibroma 4/4 n.d. 3/3
NF1 skin without phenotypic abnormality 1/1 n.d. 3/3
Non-NF1 skin over neurofibroma 0/1 n.d. 0/2
Normal, non-NF1 Skin 0/4 0/6 0/3
aSummary of the detection of MK in various samples using the techniques of ISH, Northern analysis, and immunolocalization, and is expressed as MK-positive samples/
samples analyzed. n.d., not determined.
samples which demonstrated no epidermal nor dermal MK mRNA
expression.
FGF-2 is not aberrantly expressed in NF1 skin Homozygous
loss of NF1 in Schwann cells results in aberrant angiogenic activity
and a shift of angiogenic factor expression, including upregulation
of MK, but also of FGF-2.1 In order to investigate whether
heterozygous loss of neurofibromin in skin of NF1 patients resulted
in the same shift of the angiogenic profile as observed in Schwann
cells, NF1 and non-NF1 skin was studied for expression of FGF-
2. Skin overlying a neurofibroma from an NF1 patient revealed
FGF-2 mRNA expression in the dermal layer, in blood vessels,
and sebaceous glands (n 5 3) (Fig 1g). This is the expected
distribution of FGF-2, and indeed there was no difference when
compared with normal skin from a healthy subject (n 5 3) (Fig 1h).
Thus, the shift of the angiogenic profile in neurofibromin-deficient
skin does not reflect the same angiogenic shift that was observed
in neurofibromin-deficient Schwann cells.
Midkine is a mitogen for human endothelial and neurofib-
roma-derived cells To test whether MK could contribute to
neurofibroma tumorigenesis and angiogenesis, conditioned media
from MK6 cells overexpressing human MK was used. The MK6
cell line was generated from the MK-negative adrenal carcinoma
cell line SW-13. Conditioned media from MK6 cells induced a
263.84% (mean, SD 1 2.23%) stimulation of HUVEC growth
compared with media from the parent cell line SW-13 (Fig 2).
In order to confirm that the mitogenic effects were attributable
to MK, and to further diminish the possibility that increased
proliferation is due to a secondary MK-induced secreted factor, we
Figure 2. MK is a mitogen for human endothelial and
neurofibroma-derived cells. HUVEC and Hs422T neurofibroma-
derived cells were plated at 1000 cells per well in a fibronectin coated 96
well plate in IMEM/10% fetal bovine serum. After 16 h, 100 µl of serum-
free media, SW13, or MK6 conditioned media were added in triplicate.
Cell growth was determined at day 4 after stimulation. For dose–response
analysis, heparin-affinity purified MK was used (middle panel). HUVEC
cells were plated in fibronectin coated 12-well plates at 5000 cells per well.
After 16 h, 1 ml of serum-free medium supplemented with 50, 25, 10,
and 0 µl of the 0.9 M NaCl heparin-fraction from MK6 cells and 50 µl
0.9 M NaCl fraction from control SW13 cells was added. Cell growth
was determined at day 4 after stimulation.
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partially purified the conditioned media of MK6 cells using heparin-
affinity chromatography. MK eluates at 0.9 M NaCl and we used
this fraction collected from conditioned medium of MK6 cells and
from control transfected SW13 cells in an HUVEC proliferation
assay. Using this partially purified MK, we found a concentration-
dependent stimulation of HUVEC proliferation (Fig 2). Maximal
stimulation was observed at 8 ng per ml MK with 278% induction
compared with control. This is comparable with a 80% stimulation
of HUVEC cells by the potent angiogenic factor FGF-2 at 4 ng
per ml (not shown).
Conditioned media from MK6 cells demonstrated a mitogenic
effect on the neurofibroma-derived fibroblast cell line Hs422T.
MK6 conditioned media induced a 197.53% (mean, SD 1 3.36%)
stimulation of Hs422T cells compared with SW13 conditioned
media (Fig 2).
DISCUSSION
The dysregulation of growth factors has previously been investigated
in the pathogenesis of NF1. Functional studies on neurofibromin-
deficient neurons indicate that neurotrophic factors are directly
regulated by neurofibromin, as evidenced by the survival of sensory
embryonic neurons isolated from homozygous NF1 knockout
mice in the absence of neurotrophic factors (Vogel et al, 1995).
Furthermore, a number of growth factors and growth factor
receptors that are overexpressed in neurofibromas have been
reported. These include upregulation of nerve growth factor
(Fabricant and Todaro, 1981) neuroblastoma and glial growth
inhibitor, ciliary neurotrophic factor (Asai et al, 1991), insulin-like
growth factor-2 (Hansson et al, 1988), hepatocyte growth factor
(Krasnoselsky et al, 1994; Rao et al, 1997), stem cell factor (Ryan
et al, 1994), as well as receptors for nerve growth factor (Sonnenfeld
et al, 1986), platelet derived growth factor (Kadono et al, 1994),
transforming growth factor-β (Kadono et al, 1994), and c-kit (Hirota
et al, 1993; Ryan et al, 1994).
Schwann cells, fibroblasts, and neurons have all been examined
for their role in the aberrant expression of tumor growth factors
in NF1. This report demonstrates the skin of NF1 patients as a
source of aberrant tumorigenic and angiogenic growth factor
expression. Although NF1 is a pleiomorphic disorder with highly
variable expressivity, dermal neurofibromas, cafe´-au-lait maculas,
abnormal freckling, and hyperpigmentation are predominant clinical
symptoms. With germ-line loss of NF1 therefore it appears that
the skin becomes a permissive environment for the formation of
tumors and other disorders. It has previously been demonstrated
that normal human keratinocytes express neurofibromin (Malhotra
and Ratner, 1994) and that high calcium treatment decreases
neurofibromin levels in cultured keratinocytes (Hermonen et al,
1995), but the significance of this in the symptoms of NF1 has not
been clarified. Furthermore, it is currently unknown how the
heterozygous loss of NF1 affects neurofibromin levels in ker-
atinocytes. A decreased expression of neurofibromin, however, was
found in melanocytes derived from NF1 skin (Griesser et al, 1995)
and it is possible that gene dosage is a factor in regulating
neurofibromin levels also in keratinocytes. In addition, a gene
concentration-dependent phenotype was observed in NF1 wild-
type, heterozygous and homozygous knockout mouse Schwann
cells, whereby NF11/– cells presented with intermediate proliferat-
ive response and ras-GTP levels (Kim et al, 1995). This gene
dosage-dependent phenotype is most likely due to intermediate
neurofibromin levels. Whether MK upregulation in NF1 skin is a
direct effect of differential neurofibromin expression needs to
be clarified.
We suggest that an increased cutaneous concentration of MK
due to mutations of NF1 may contribute to the preferential
formation of symptoms in the skin. Although neurofibromas may
clearly form in the absence of MK expression in the skin (Fig 1b),
the increased concentration of this growth factor and its diffusion
into subepidermal layers of the skin may lower the threshold for
abnormal cells to induce angiogenesis and to facilitate tumorigenesis.
Indeed, it has been reported that neurofibromas from NF1 patients
are highly vascularized (Arbiser et al, 1998), which would be
promoted by a difference in the dermal angiogenic environment
associated with the loss of NF1. We and others have shown that
MK acts as a mitogen for both endothelial cells (Choudhuri et al,
1997; Kadomatsu et al, 1997). Here we show that MK is also
a potent mitogen for neurofibroma-derived cells of fibroblast
morphology. Thus, its expression by keratinocytes could support
the growth of the various cell types comprising neurofibromas,
including fibroblasts and vascular elements. Furthermore, MK has
been shown to stimulate the expression of collagen by dermal
fibroblasts (Yamada et al, 1997). The increased expression of matrix
proteins in neurofibromas is well characterized (Gutmann and
Collins, 1995), and wound healing in NF1 heterozygous knockout
mice results in abnormal fibrosis.2 In conclusion, we introduce the
skin as a source of dysregulated growth factors in NF1, and suggest
the further study of the angiogenic factor MK in NF1 pathogenesis.
We would like to thank Dr. Nancy Ratner of the University of Cincinatti College
of Medicine for helpful contributions. This work was supported by a grant from
Neurofibromatosis, Inc. to RLM.
REFERENCES
Arbiser JL, Flynn E, Barnhill RL: Analysis of vascularity of human neurofibromas. J
Am Acad Dermatol 38(6 Part 1):950–954, 1998
Asai K, Hotta T, Nakanishi K, Ito J, Tanaka R, Otsuka T, Matsui N, Kato T: von
Recklinghausen neurofibroma produces neuronal and glial growth-modulating
factors. Brain Res 60:312–319, 1991
Bernards A: Neurofibromatosis type 1 and Ras-mediated signaling: filling in the
GAPs. Biochim Biophys Acta 1242:43–59, 1995
Cattoretti G, Pileri S, Parravicin C: Antigen unmasking on formalin-fixed, paraffin
embedded tissue sections. J Pathol 171:83–98, 1993
Choudhuri R, Zhang H-T, Donnini S, Ziche M, Bicknell R: An angiogenic role
for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res
57:1814–1819, 1997
De Clue JE, Cohen BD, Lowy DR: Identification and characterization of the
neurofibromatosis type 1 protein product. Proc Natl Acad Sci USA 88(22):9914–
9918, 1991
Fabricant RN, Todaro GJ: Increased serum levels of nerve growth factor in von
Recklinghausen9s disease. Arch Neurol 38(7):401–405, 1981
Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A: Pleiotrophin stimulates
fibroblasts and endothelial and epithelial cells and is expressed in human cancer.
J Biol Chem 267(36):25889–25897, 1992
Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG: Midkine
and pleiotrophin expression in normal and malignant breast tissue. Cancer
74(5):1584–1590, 1994
Griesser J, Kaufmann D, Eisenbarth I, Ba¨uerle C, Krone W: Ras-GTP regulation is
not altered in cultured melanocytes with reduced levels of neurofibromin
derived from patients with neurofibromatosis 1 (NF1). Biol Chem Hoppe-Seyler
376:91–101, 1995
Gutmann DH, Collins FS. von Recklinghausen neurofibromatosis. In: Scriver et al
(eds). The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York:
McGraw-Hill, 667–696, 1995
Gutmann DH, Wood DL, Collins FS: Identification of the neurofibromatosis type
1 gene product. Proc Natl Acad Sci USA 88(21):9658–9662, 1991
Hansson HA, Lauritzen C, Lossing C, Petruson K: Somatomedin C as tentative
pathogenic factor in neurofibromatosis. Scand J Plast Reconstr Surg Hand Surg
22 (1):7–13, 1988
Hermonen J, Hirvonen O, Yla-Outinen H, et al: Neurofibromin: expression by
normal human keratinocytes in vivo and in vitro and in epidermal malignancies.
Lab Invest 73(2):221–228, 1995
Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y: Possible involvement
of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues.
Arch Pathol Lab Med 117(10):996–999, 1993
Inazumi T, Tajima S, Nishikawa T, Kadamatsu K, Muramatsu H, Muramatsu T:
Expression of the retinoid inducible polypeptide, midkine, in human epidermal
keratinocytes. Arch Dermatol Res 289:471–475, 1997
Kadomatsu K, Huang R-P, Suganuma T, Murata F, Muramatsu T: A retinoic acid
responsive gene MK found in the teratocarcinoma system is expressed in
spatially and temporally manner during mouse embryogenesis. J Cell Biol
110:607–616, 1990
2Ratner N, Atit R, Wenstrup R, Crowe M: Increased matrix deposition
by neurofibromin-deficient fibroblasts: evidence for a Ras-independent
phenotype. Society for Neuroscience 27th Annual Meeting 23:35.13, 1997
(Abstr.)
402 MASHOUR ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Kadomatsu K, Hagihara M, Akhter S, Fan Q-W, Muramatsu H, Muramatsu T:
Midkine induces the transformation of NIH3T3 cells. Br J Cancer 75(3):354–
359, 1997
Kadono T, Soma Y, Takehara K, Nakagawa H, Ishibashi Y, Kikuchi K: The growth
regulation of neurofibroma cells in neurofibromatosis type 1: increased responses
to PDGF-BB and TGF-beta 1. Biochem Biophys Res Commun 198(3):827–
834, 1994
Kim HA, Rosenbaum T, Marchionni MA, Ratner N, DeClue JE: Schwann cells
from neurofibromin deficient mice exhibit activation of p21-ras, inhibition of
cell proliferation and morphological changes. Oncogene 11:325–335, 1995
Krasnoselsky A, Massay MJ, DeFrances MC, Michalopoulos G, Zarnegar R, Ratner
N: Hepatocyte growth factor is a mitogen for Schwann cells and is present in
neurofibromas. J Neurosci 82(5):733–742, 1994
Mahoney SA, Perry M, Seddon A, Bohlen P, Haynes L: Transglutaminase forms
midkine homodimers in cerebellar neurons and modulates the neurite-
outgrowth response. Biochem Biophys Res Commun 224:147–152, 1996
Malhotra R, Ratner N: Localization of neurofibromin to keratinocytes and
melanocytes in developing rat and human skin. J Invest Dermatol 102(5):812–
818, 1994
Matsumoto K, Wanaka A, Mori T, et al: Localization of pleiotrophin and midkine
in the postnatal developing cerebellum. Neurosci Lett 178(2):216–220, 1994
Mitsiadis TA, Salmivirta M, Muramatsu T, et al: Expression of the heparin-binding
cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with
epithelial–mesenchymal interactions during fetal development and
organogenesis. Development 121:37–51, 1995
Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T: Midkine, a
retinoic acid inducible growth/differentiation factor: immunochemical evidence
for the function and distribution. Dev Biol 159:392–402, 1993
Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur
GM: Differential expression of pleiotrophin and midkine in advanced
neuroblastomas. Cancer Res 55(8):1792–1797, 1995
Nakamoto M, Matsubara S, Miyauchi T, Obama H, Ozawa M, Muramatsu T:
A new family of heparin-binding growth/differentiation factors: differential
expression of the midkine (MK) and HB-GAM genes during development. J
Biochem 112:346–349, 1992
Nakamura T, Nemoto T, Arai M, et al: Specific expression of the neurofibromatosis
type 1 gene (NF1) in the hamster Schwann cell. Am J Pathol 144(3):549–
555, 1994
O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: The angiogenic factor
midkine is expressed in bladder cancer, and overexpression correlates with a
poor outcome in patients with invasive cancers. Cancer Res 56(11):2515–
2518, 1996
Panoskaltsis-Mortari A, Bucy RP: In situ hybridization with digoxigenin-labeled
RNA probes: facts and artifacts. Biotechniques 18(2):300–307, 1995
Rao UN, Sonmez-Alpan E, Michalopoulos G: Hepatocyte growth factor and c-
MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol
28(9):1066–1070, 1997
Ryan JJ, Klein KA, Neuberger TJ, et al: Role for the stem cell factor/KIT
complex in Schwann cell neoplasia and mast cell proliferation associated with
neurofibromatosis. J Neurosci Res 37 (3):415–432, 1994
Sawada S, Florell S, Purandare SM, Ota M, Stephens K, Viscochil D: Identification
of NF1 mutations in both alleles of a dermal neurofibroma. Nature Genet
14:110–112, 1996
Sonnenfeld KH, Bernd P, Sobue G, Lebwohl M, Rubenstein AE: Nerve growth
factor receptors on dissociated neurofibroma Schwann-like cells. Cancer Res
46(3):1446–1452, 1986
Vogel KS, Brannan CI, Jenkins NA, Copeland NG, Parada LF: Loss of neurofibromin
results in neurotrophin-independent survival of embryonic sensory and
sympathetic neurons. Cell 82(5):733–742, 1995
Yamada H, Inazumi T, Tajima Muramatsu H, Muramatsu T: Stimulation of
collagen expression and glycosaminoglycan synthesis by midkine in human
skin fibroblasts. Arch Dermatol Res 289:429–433, 1997
